HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

G Fabbrini Selected Research

incobotulinumtoxinA

5/2012Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
3/2010Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
4/2006No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


G Fabbrini Research Topics

Disease

8Parkinson Disease (Parkinson's Disease)
11/2013 - 10/2000
4Parkinsonian Disorders (Parkinsonism)
05/2019 - 12/2000
3Blepharospasm
08/2011 - 08/2007
3Dystonia (Limb Dystonia)
07/2010 - 07/2005
3Dementia (Dementias)
02/2009 - 12/2001
3Migraine Disorders (Migraine)
02/2002 - 02/2000
2Dyskinesias (Dyskinesia)
02/2011 - 05/2007
2Hemifacial Spasm
08/2007 - 04/2006
2Hallucinations (Hallucination)
05/2007 - 04/2002
2Alzheimer Disease (Alzheimer's Disease)
01/2006 - 12/2000
2Psychotic Disorders (Schizoaffective Disorder)
12/2001 - 12/2000
1Corticobasal Degeneration
05/2019
1Tourette Syndrome (Tourette's Syndrome)
01/2017
1Overactive Urinary Bladder (Overactive Bladder)
05/2012
1Benign essential blepharospasm
08/2011
1Eye Diseases (Eye Disease)
08/2011
1Camptocormia
02/2009
1Torticollis (Wryneck)
06/2008
1Primary Cervical Dystonia
06/2008
1Paresis (Hemiparesis)
05/2007
1Muscle Weakness
04/2006
1Spasm (Spasms)
04/2006
1Disorders of Excessive Somnolence (Hypersomnia)
10/2003
1Mitochondrial Myopathies (Mitochondrial Myopathy)
03/2001
1Mitochondrial Diseases (Mitochondrial Disease)
03/2001
1Cognitive Dysfunction
02/2001
1Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome)
02/2001
1Hypersensitivity (Allergy)
02/2000

Drug/Important Bio-Agent (IBA)

4Botulinum Toxins (Botulinum Toxin)IBA
05/2012 - 04/2006
4Levodopa (L Dopa)FDA LinkGeneric
02/2011 - 07/2005
4Dopamine (Intropin)FDA LinkGeneric
09/2010 - 02/2000
3incobotulinumtoxinAFDA Link
05/2012 - 04/2006
3Type A Botulinum Toxins (Botox)FDA Link
03/2010 - 04/2006
2CoffeeFDA Link
08/2011 - 08/2007
2Donepezil (Aricept)FDA LinkGeneric
04/2002 - 02/2001
2Cholinesterase Inhibitors (Anticholinesterases)IBA
04/2002 - 02/2001
1tau Proteins (tau Protein)IBA
05/2019
1Brain-Derived Neurotrophic Factor (BDNF)IBA
01/2017
1Dopamine Agents (Dopaminergic Agents)IBA
10/2003
1Cholinergic Agents (Cholinergics)IBA
04/2002
1Neurotransmitter Agents (Neurotransmitter)IBA
02/2002
1Antipsychotic Agents (Antipsychotics)IBA
12/2001
1Electron Transport Complex IV (Cytochrome c Oxidase)IBA
03/2001
1Mitochondrial DNA (mtDNA)IBA
03/2001
1AntibodiesIBA
02/2000
1Dopamine Receptors (Dopamine Receptor)IBA
02/2000

Therapy/Procedure

5Therapeutics
11/2013 - 10/2000
2Transcranial Magnetic Stimulation
09/2010 - 01/2006
1Drug Therapy (Chemotherapy)
11/2013
1Duration of Therapy
02/2009
1Activities of Daily Living (ADL)
02/2001